Thinly traded nano cap NanoViricides (NYSEMKT:NNVC) perks up 7% premarket on light volume in response to its announcement that it has completed genetic toxicology testing on NV-HHV-101, a skin cream for the potential treatment of shingles. The data will support an IND application.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.